Sernova Team Participates at Key US Life Sciences Event: 2014 BIO International Convention, San Diego

LONDON, ONTARIO--(Marketwired - June 24, 2014) - Sernova Corp. (TSX VENTURE:SVA), a clinical stage company developing disruptive medical technologies for the long-term treatment of chronic diseases such as diabetes and haemophilia announced today that it is participating at the US BIO International Convention in San Diego, June 23-26^th.

"This is an excellent occasion for Sernova to present to international institutions, pharma and potential collaborators to update attendees on our progress and pipeline," remarked Dr. Philip Toleikis, President and CEO.

The convention is an important annual business development forum which allows high-level executives and influential decision makers attending BIO to liaise with key players in the industry, form partnerships, and evaluate emerging technologies.

"Sernova's entire business development team is attending and has numerous one-on-one meetings booked to discuss its proprietary platform - many important collaborations mark their origins to BIO," remarked Kevin Egan, chair of Sernova's Business Advisory Board.

About Sernova

Sernova Corp. is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including haemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch™, an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova's proprietary technologies.

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.